OBJECTIVES: The objective of this study was to examine factors that are associated with aggression that is responsive versus refractory to individualized optimization of stimulant monotherapy among children with attention-deficit/hyperactivity disorder (ADHD). METHODS: Children who were aged 6 to 13 years and had ADHD, either oppositional defiant disorder or conduct disorder, significant aggressive behavior, and a history of insufficient response to stimulants completed an open stimulant monotherapy optimization protocol. Stimulant titration with weekly assessments of behavior and tolerability identified an optimal regimen for each child. Families also received behavioral therapy. Parents completed the Retrospective-Modified Overt Aggression Scale (R-MOAS) at each visit. Children were classified as having stimulant-refractory aggression on the basis of R-MOAS ratings and clinician judgment. Differences that pertained to treatment, demographic, and psychopathology between groups with stimulant monotherapy-responsive and -refractory aggression were evaluated. RESULTS: Aggression among 32 (49.3%) of 65 children was reduced sufficiently after stimulant dosage adjustment and behavioral therapy to preclude adjunctive medication. Those who responded to stimulant monotherapy were more likely to benefit from the protocol's methylphenidate preparation (once-daily, triphasic release), showed a trend for lower average dosages, and received fewer behavioral therapy sessions than did children with stimulant-refractory aggression. Boys, especially those with higher ratings of baseline aggression and of depressive and manic symptoms, more often exhibited stimulant-refractory aggression. CONCLUSIONS: Among children whose aggressive behavior develops in the context of ADHD and of oppositional defiant disorder or conduct disorder, and who had insufficient response to previous stimulant treatment in routine clinical care, systematic, well-monitored titration of stimulant monotherapy often culminates in reduced aggression that averts the need for additional agents.
OBJECTIVES: The objective of this study was to examine factors that are associated with aggression that is responsive versus refractory to individualized optimization of stimulant monotherapy among children with attention-deficit/hyperactivity disorder (ADHD). METHODS:Children who were aged 6 to 13 years and had ADHD, either oppositional defiant disorder or conduct disorder, significant aggressive behavior, and a history of insufficient response to stimulants completed an open stimulant monotherapy optimization protocol. Stimulant titration with weekly assessments of behavior and tolerability identified an optimal regimen for each child. Families also received behavioral therapy. Parents completed the Retrospective-Modified Overt Aggression Scale (R-MOAS) at each visit. Children were classified as having stimulant-refractory aggression on the basis of R-MOAS ratings and clinician judgment. Differences that pertained to treatment, demographic, and psychopathology between groups with stimulant monotherapy-responsive and -refractory aggression were evaluated. RESULTS:Aggression among 32 (49.3%) of 65 children was reduced sufficiently after stimulant dosage adjustment and behavioral therapy to preclude adjunctive medication. Those who responded to stimulant monotherapy were more likely to benefit from the protocol's methylphenidate preparation (once-daily, triphasic release), showed a trend for lower average dosages, and received fewer behavioral therapy sessions than did children with stimulant-refractory aggression. Boys, especially those with higher ratings of baseline aggression and of depressive and manic symptoms, more often exhibited stimulant-refractory aggression. CONCLUSIONS: Among children whose aggressive behavior develops in the context of ADHD and of oppositional defiant disorder or conduct disorder, and who had insufficient response to previous stimulant treatment in routine clinical care, systematic, well-monitored titration of stimulant monotherapy often culminates in reduced aggression that averts the need for additional agents.
Authors: Daniel F Connor; Stephen J Glatt; Ivan D Lopez; Denise Jackson; Richard H Melloni Journal: J Am Acad Child Adolesc Psychiatry Date: 2002-03 Impact factor: 8.829
Authors: L L Greenhill; H B Abikoff; L E Arnold; D P Cantwell; C K Conners; G Elliott; L Hechtman; S P Hinshaw; B Hoza; P S Jensen; J S March; J Newcorn; W E Pelham; J B Severe; J M Swanson; B Vitiello; K Wells Journal: J Am Acad Child Adolesc Psychiatry Date: 1996-10 Impact factor: 8.829
Authors: W E Pelham; E M Gnagy; L Burrows-Maclean; A Williams; G A Fabiano; S M Morrisey; A M Chronis; G L Forehand; C A Nguyen; M T Hoffman; T M Lock; K Fielbelkorn; E K Coles; C J Panahon; R L Steiner; D L Meichenbaum; A N Onyango; G D Morse Journal: Pediatrics Date: 2001-06 Impact factor: 7.124
Authors: Ellen Leibenluft; Dennis S Charney; Kenneth E Towbin; Robinder K Bhangoo; Daniel S Pine Journal: Am J Psychiatry Date: 2003-03 Impact factor: 18.112
Authors: Jeffrey H Newcorn; Virginia K Sutton; Shuyu Zhang; Timothy Wilens; Christopher Kratochvil; Graham J Emslie; Deborah N D'souza; Leslie M Schuh; Albert J Allen Journal: J Am Acad Child Adolesc Psychiatry Date: 2009-12 Impact factor: 8.829
Authors: James G Waxmonsky; Daniel A Waschbusch; Peter Belin; Tan Li; Lysett Babocsai; Hugh Humphery; Meaghan E Pariseau; Dara E Babinski; Martin T Hoffman; Jenifer L Haak; Jessica R Mazzant; Gregory A Fabiano; Jeremy W Pettit; Negar Fallahazad; William E Pelham Journal: J Am Acad Child Adolesc Psychiatry Date: 2015-12-28 Impact factor: 8.829
Authors: Yizhao Ni; Drew Barzman; Alycia Bachtel; Marcus Griffey; Alexander Osborn; Michael Sorter Journal: Int J Med Inform Date: 2020-04-25 Impact factor: 4.046
Authors: Matteo Pardini; Frank Krueger; Colin A Hodgkinson; Vanessa Raymont; Maren Strenziok; Mario Amore; Eric M Wassermann; David Goldman; Jordan H Grafman Journal: CNS Spectr Date: 2014-03-11 Impact factor: 3.790
Authors: Michael L Birnbaum; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; John M Kane; Christoph U Correll Journal: Curr Psychiatry Rep Date: 2013-08 Impact factor: 5.285
Authors: Joseph C Blader; Steven R Pliszka; Vivian Kafantaris; Carmel A Foley; Judith A Crowell; Gabrielle A Carlson; Colin L Sauder; David M Margulies; Christa Sinha; Jeffrey Sverd; Thomas L Matthews; Brigitte Y Bailey; W Burleson Daviss Journal: J Am Acad Child Adolesc Psychiatry Date: 2013-09-25 Impact factor: 8.829
Authors: Joseph C Blader; Steven R Pliszka; Vivian Kafantaris; Colin Sauder; Jonathan Posner; Carmel A Foley; Gabrielle A Carlson; Judith A Crowell; David M Margulies Journal: J Child Adolesc Psychopharmacol Date: 2016-01-08 Impact factor: 2.576
Authors: Raman Baweja; Peter J Belin; Hugh H Humphrey; Lysett Babocsai; Meaghan E Pariseau; Daniel A Waschbusch; Martin T Hoffman; Opeolowa O Akinnusi; Jenifer L Haak; William E Pelham; James G Waxmonsky Journal: J Child Adolesc Psychopharmacol Date: 2016-01-15 Impact factor: 2.576